Skip to main content
. Author manuscript; available in PMC: 2010 Jan 29.
Published in final edited form as: J Invest Dermatol. 2009 Apr 2;129(9):2156. doi: 10.1038/jid.2009.61

Figure 4. Competition ELISA of PF sera binding by anti-desmoglein 1 (Dsg1) single-chain variable fragment (scFv) mAbs.

Figure 4

Competition ELISA of 40 PF sera was carried out to see if the binding against standard Dsg1 ELISA plates of PF sera was blocked by adding anti-Dsg1scFv mAbs. 3–30/3h (shown in orange), 3–97/1c, 3–94/O18O8 (shown in green) and 1–18/L12 (shown in blue) were used as competitors. When >20% inhibition was considered as significant (shown in broken line), the bindings were blocked by pathogenic 3–30/3h mAb in 29 PF sera. 3–97/1c and 3–94/O18O8, which recognized the precursor form, blocked the binding in 10 PF sera.